Gilead Sciences | GILD - Ebitda


Gilead Sciences reported $-9.31B in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 3.86B 1.28B Mar/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 222.32M 76.27M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
J&J USD 8.99B 721M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Moderna USD -1.26B 468M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026